VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
KZIA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
KZIAKazia Therapeutics Limited
$13.10$21M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksKZIAP/E History

KZIA logoKazia Therapeutics Limited (KZIA) P/E Ratio History

Deep Value

Trading at -1.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2002–2003

Current P/E (TTM)
-1.0x
-113% vs 5Y avg
5Y Avg P/E
7.5x
Median 7.6x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-1.0x
Min7.4xMedian7.6xMax7.6x
TTM EPS$-16.24
Price$13.10
Earnings YieldN/A
EPS Growth (1Y)65.6%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of July 8, 2026, Kazia Therapeutics Limited (KZIA) trades at a price-to-earnings ratio of -1.0x, with a stock price of $13.10 and trailing twelve-month earnings per share of $-16.24.

The current P/E is 113% below its 5-year average of 7.5x. Over the past five years, KZIA's P/E has ranged from a low of 7.4x to a high of 7.6x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.4x, KZIA trades at a 104% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.

Relative to the broader market, KZIA trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KZIA DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

KZIA Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-1.0vs23.4
-104%
Below Sector
vs. S&P 500
-1.0vs25.9
-104%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 66% EPS growth (1Y)

KZIA P/E vs Peers

Oncology Therapeutics Developers peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
TGTX logoTGTXTG Therapeutics, Inc.
$8B19.3Lowest-Best+1747%Best

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

KZIA Historical P/E Data (2002–2003)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2003 Q4Jun 30 2003$5764.95$755.907.6x+1%
FY2002 Q4Jun 30 2002$2056.55$276.907.4x-1%

Average P/E for displayed period: 7.5x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

24+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

KZIA — Frequently Asked Questions

Quick answers to the most common questions about buying KZIA stock.

What is KZIA's P/E ratio?

Kazia Therapeutics Limited (KZIA) trailing twelve-month P/E ratio is -1.0x, based on TTM diluted EPS of $-16.24. The 5-year average P/E is 7.5x and the historical range spans 7.4x to 7.6x.

Is KZIA stock overvalued or undervalued?

KZIA trades at -1.0x P/E, below its 5-year average of 7.5x. At the 0th percentile of its historical range (7.4x–7.6x), the stock is priced at a discount to its own history.

Is KZIA stock expensive?

No, KZIA is not expensive on a historical basis. The current P/E of -1.0x is below the 5-year average of 7.5x and sits at the 0th percentile of its valuation range.

What is KZIA's historical P/E range?

Over the past 5 years, KZIA's P/E ratio has ranged from 7.4x to 7.6x, with a median of 7.6x and an average of 7.5x. The current P/E of -1.0x places the stock at the 0th percentile of this range. Full historical data spans 2002–2003.

How does KZIA's P/E compare to the S&P 500?

KZIA trades at -1.0x P/E versus the S&P 500 median of 25.9x. The 104% discount to the market suggests lower growth expectations or perceived higher risk.

How does KZIA's valuation compare to Healthcare peers?

Kazia Therapeutics Limited P/E of -1.0x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is KZIA's PEG ratio?

KZIA PEG ratio is N/A, based on a P/E of -1.0x and EPS growth of 65.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is KZIA's earnings yield?

KZIA earnings yield is N/A, the inverse of its -1.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

KZIA P/E Ratio History (2002–2003)

Quarterly valuation multiple from closing price and trailing EPS

Current7.6x
Period Avg7.5x
Range7.4x - 7.6x
Change+3%
2 quartersJun 30, 2002 - Jun 30, 2003